Analysis of Serious Adverse Event Reporting for Patients Enrolled in Cancer Clinical Trials During the COVID-19 Pandemic.
作者信息
Ragavan Meera V, Legaspi Nichole, LaLanne Alyssa, Hong Julian C, Small Eric J, Borno Hala T
机构信息
Division of Hematology and Oncology, Department of Medicine, University of California, San Francisco, San Francisco.
Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, San Francisco.
出版信息
JAMA Oncol. 2022 Dec 1;8(12):1849-1851. doi: 10.1001/jamaoncol.2022.4919.
Abstract
摘要
相似文献
1
Analysis of Serious Adverse Event Reporting for Patients Enrolled in Cancer Clinical Trials During the COVID-19 Pandemic.新冠疫情期间癌症临床试验入组患者严重不良事件报告分析
JAMA Oncol. 2022 Dec 1;8(12):1849-1851. doi: 10.1001/jamaoncol.2022.4919.
2
Effects of the COVID-19 Pandemic on Spontaneous Reporting: Global and National Time-series Analyses.新冠疫情对自发报告的影响：全球和国家时间序列分析。
Clin Ther. 2021 Feb;43(2):360-368.e5. doi: 10.1016/j.clinthera.2020.12.008. Epub 2020 Dec 18.
3
Convalescent plasma or hyperimmune immunoglobulin for people with COVID-19: a rapid review.新冠康复者血浆或超免疫球蛋白用于新冠患者：快速综述
Cochrane Database Syst Rev. 2020 May 14;5(5):CD013600. doi: 10.1002/14651858.CD013600.
4
Follow-Up on the Use of Machine Learning in Clinical Quality Assurance: Can We Detect Adverse Event Under-Reporting in Oncology Trials?机器学习在临床质量保证中的应用跟踪：我们能否在肿瘤学试验中检测到不良事件报告不足的情况？
Drug Saf. 2020 Mar;43(3):295-296. doi: 10.1007/s40264-019-00894-3.
5
Adverse Event Reporting in Clinical Trials: Time to Include Duration as Well as Severity.临床试验中的不良事件报告：是时候将持续时间和严重程度都包括在内了。
Oncologist. 2018 Jan;23(1):1. doi: 10.1634/theoncologist.2017-0437. Epub 2017 Nov 20.
6
Adverse event reporting in cancer clinical trial publications.癌症临床试验出版物中的不良事件报告。
J Clin Oncol. 2014 Jan 10;32(2):83-9. doi: 10.1200/JCO.2013.52.2219. Epub 2013 Dec 9.
7
Supporting quality and patient safety in cancer clinical trials.在癌症临床试验中支持质量与患者安全。
Clin J Oncol Nurs. 2011 Jun;15(3):263-5. doi: 10.1188/11.CJON.263-265.
8
How to Investigate a Serious Adverse Event Reported During a Clinical Trial for a COVID-19 Vaccine.如何调查在COVID-19疫苗临床试验期间报告的严重不良事件。
Drug Saf. 2021 Jan;44(1):1-5. doi: 10.1007/s40264-020-01018-y. Epub 2020 Nov 21.
9
Global COVID-19 pandemic and reporting behavior - An analysis of the Food and Drug Administration adverse events reporting system.全球 COVID-19 大流行与报告行为 - 对食品和药物管理局不良事件报告系统的分析。
Pharmacoepidemiol Drug Saf. 2021 Jun;30(6):707-715. doi: 10.1002/pds.5217. Epub 2021 Mar 17.
10
The COVID-19 pandemic and new clinical trial activations.新型冠状病毒肺炎大流行与新临床试验的开展。
Trials. 2021 Apr 8;22(1):260. doi: 10.1186/s13063-021-05219-3.
引用本文的文献
1
Impact of the COVID-19 Pandemic on Cancer Clinical Trials: Alliance for Clinical Trials in Oncology Experience (Alliance A152022).2019冠状病毒病大流行对癌症临床试验的影响：肿瘤临床试验联盟经验（联盟A152022）
J Clin Trials. 2024;14(5). Epub 2024 Jul 25.
2
Patient Safety and Satisfaction With Fully Remote Management of Radiation Oncology Care.患者安全和对放射肿瘤学治疗完全远程管理的满意度。
JAMA Netw Open. 2024 Jun 3;7(6):e2416570. doi: 10.1001/jamanetworkopen.2024.16570.
3
Evaluating Immune Checkpoint Blockade in Metastatic Castration-Resistant Prostate Cancers with Deleterious CDK12 Alterations in the Phase 2 IMPACT Trial.在 2 期 IMPACT 试验中，评估 CDK12 有害改变的转移性去势抵抗性前列腺癌的免疫检查点阻断。
Clin Cancer Res. 2024 Aug 1;30(15):3200-3210. doi: 10.1158/1078-0432.CCR-24-0400.
4
Safety of Secukinumab from 1 Million Patient-Years of Exposure: Experience from Post-Marketing Setting and Clinical Trials.司库奇尤单抗100万患者年暴露量的安全性：来自上市后环境和临床试验的经验。
Dermatol Ther (Heidelb). 2024 Mar;14(3):729-743. doi: 10.1007/s13555-024-01122-2. Epub 2024 Mar 7.
5
The Real-World Outcome of First Line Atezolizumab in Extensive-Stage Small Cell Lung Cancer: A Multicenter Prospective Cohort Study.一线阿特珠单抗治疗广泛期小细胞肺癌的真实世界结局：一项多中心前瞻性队列研究。
Cancer Res Treat. 2024 Apr;56(2):422-429. doi: 10.4143/crt.2023.913. Epub 2023 Oct 23.
Zotero 插件